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Cell therapy has been established as an important ﬁeld of research with considerable progress in the last years. At the same time,
the progressive aging of the population has highlighted the importance of discovering therapeutic alternatives for diseases of high
incidence and disability, such as stroke. Menstrual blood is a recently discovered source of stem cells with potential relevance for
the treatment of stroke. Migration to the infarct site, modulation of the inﬂammatory reaction, secretion of neurotrophic factors,
and possible diﬀerentiation warrant these cells as therapeutic tools. We here propose the use of autologous menstrual blood cells
in the restorative treatment of the subacute phase of stroke. We highlight the availability, proliferative capacity, pluripotency,
and angiogenic features of these cells and explore their mechanistic pathways of repair. Practical aspects of clinical application of
menstrual blood cells for stroke will be discussed, from cell harvesting and cryopreservation to administration to the patient.
1.Introduction
Cell therapy has established itself as an important ﬁeld of
research with considerable progress in the last years. Sev-
eral disorders, including those of inﬂammatory, traumatic,
degenerative, and autoimmune nature, are listed as potential
targets for stem cell application. While the bone marrow
leads the investigations, other sources of stem cells have
been explored, searching for cells with higher plasticity and
tissues with facilitated harvesting [1]. Disposable tissues,
such as the amniotic ﬂuid, placenta, and, more recently,
menstrual blood, are being investigated as potential sources
of stem cells for therapy [2–4]. The immature phenotype,
high proliferative potential, and immunomodulatory eﬀects
of these cells suggest them as powerful tools for repair.
Neurovascular diseases are the third leading cause of
death in the United States and the ﬁrst cause of chronic dis-
ability[5,6].Agingofthepopulationandchangesinlifestyle,
especially in developed countries, contribute to the progres-
siveincreaseintheincidenceofthesedisorders,morespeciﬁ-
cally stroke [7]. On the other hand, treatment is limited, and
the only approved therapeutic agent for ischemic stroke is
tissue plasminogen activator (tPA). More limiting, however,
is the time window for tPA application, restricted to up to 32 Journal of Biomedicine and Biotechnology
hours after symptom onset [8]. As result, a report from 2008
estimatedthatonly1.8to2.1%ofallstrokepatientshadbeen
treated with tPA in the United States [9]. It is clear, therefore,
that therapeutic alternatives are warranted for the remaining
stroke-aﬀected patients which, excluded from tPA beneﬁts,
are exposed to the chronic consequences of the disease.
Menstrual blood cell injections are proposed as a re-
storative therapy after stroke, aiming to provide function-
al improvement and, therefore, decrease disability of the
aﬀectedpatients.Migrationtothesiteofinjury,immunomo-
dulation, and secretion of neurotrophic factors are their
main footholds as therapeutic agents. When compared to
bone marrow-derived cells, menstrual blood cells present
more immature phenotype and behavior, albeit maintaining
the characteristic adult stem cell safety [4–10]. Experimental
studies have demonstrated beneﬁts of menstrual blood cell
administration, with tissue repair and functional improve-
ment, not only in the central nervous system, but also in
the heart and ischemic limbs [10–13]. Cell diﬀerentiation,
although demonstrable in vitro, is still heterogeneously
reported in the literature, and its relevance to the ﬁnal
outcome is not yet established. Of more importance may be
theendogenouspathwaysofrepair,whicharealsostimulated
by the administrated cells.
This paper aims to characterize menstrual blood cells,
describe their possible mechanisms of repair in stroke, and,
ﬁnally,discusspracticalaspectsofautologous,thuspersonal-
ized, application. At this time, however, the use of menstrual
blood cells for autologous transplantation is restricted to the
female population, regarding autologous use.
2. The Interaction between
Stem Cells and Inﬂammation in Stroke
Theinjurythatfollowsstrokeincludestheinfarctcore,which
harbors the tissue that evolves almost instantly to death due
to ischemia, and the penumbra area, which surrounds the
core and that maintains viable, yet nonfunctional, tissue
[14]. While the lesion in the core is mostly irreversible, the
penumbra area may be rescued, and its fate depends upon
severity of the ischemia and time elapsed before restoring
blood ﬂow [15]. Treatment with tPA is the ﬁrst attempt to
rescue the penumbra area [16]. Earlier destruction of the
clot, restoring blood ﬂow, signiﬁcantly improves functional
outcome of patients. However, application of tPA after the
3-hour time window increases the risk of hemorrhagic
transformation of the ischemic stroke, therefore limiting its
use to a small, fortunate group of patients that are able to
reach the emergency room and complete neurological triage
in time to be treated [17]. Therefore, secondary strategies
to promote restoration of the penumbra area are strongly
warranted.
Inﬂammation is settled shortly after the ischemic insult
and plays a dual role in stroke [18]. Microglial activation
leads to the inﬂammatory events, resulting in blood-brain-
barrier leakage, edema, hemorrhage, and leukocyte inﬁl-
tration [19, 20]. The migration of attracted cells from the
systemic circulation ampliﬁes the inﬂammatory response,
that culminates with release of cytokines, nitric oxide and
free radicals, further microglial and astrocytic activation,
all of which contribute to the worsening of the neurotoxic
environment. Therefore, while inﬂammation is important
to promote clearance of debris, scavenge excess neurotrans-
mitters from the extracellular space, control water and ion
homeostasis, and increase the production of neurotrophic
factors, it may also promote secondary damage to the
nervous tissue [21]. Additionally, the scar tissue generated
by the reactive astrocytes, encapsulating the infarcted area
and protecting the remaining healthy brain from further
damage, interferes with the repairing mechanisms, such
as migration of stem cells and angiogenesis. In summary,
inﬂammation is necessary and beneﬁcial in the initial hours
after stroke, however, as time progresses, interventions are
needed to restrain the aberrant immunological response and
thus protect the brain from further damage.
Cell therapy modulates the inﬂammatory response at the
same time that stimulates repairing pathways. The results are
improved when the cells are applied according to the dynam-
ics of the inﬂammatory response. Therefore, interventions in
theﬁrst24hoursfollowingstrokearemainlyneuroprotective
[22] and aim to restore vessel permeability. Treatment with
tPA is indicated in this phase, therefore preventing further
neuronal death. Thereafter, inﬂammation settles itself, with
maximum intensity during the ﬁrst week after stroke, during
which the stem cells have their best applications, promoting
restoration of the penumbra area. Injected intravenously,
stem cells migrate to the site of injury and opportunely
interact with the inﬂammatory environment, modulating
its deleterious eﬀects and at the same time maximizing
its beneﬁcial aspects [23]. Changes in the immunological
proﬁle towards a less inﬂammatory response, increasing of
cells with regulatory function, decreasing of inﬂammatory
cytokinesandreversalofastrocyticreactivityaredescribedas
modulatoryeﬀectsofstemcells[24,25].Moreover,cytokines
andchemokinessecretedbythedamagedtissuecanstimulate
the diﬀerentiation of the injected cells into cell types of
interest for repair [26]. Still in the inﬂammatory context,
stem cells secrete neurotrophic factors, which in turn stim-
ulate neuronal survival and endogenous repairing pathways
[23, 25]. Once inﬂammation decreases, after approximately
one month after stroke, according to animal studies, cells are
no longer attracted to the damage site or are stimulated to
diﬀerentiate in situ [27]. However, repair can still be pro-
moted through local implantation of prediﬀerentiated cells.
The use of undiﬀerentiated cells through intravenous
route seems to be the best approach for clinical translation
since it is minimally invasive and possesses multiple thera-
peutic pathways. On one end of the spectrum of diﬀerentia-
tion, embryonic cells have the advantage of high plasticity,
trophic support, and proliferation [28, 29]. However, the
risks of uncontrolled proliferation and teratogenicity, among
other problems associated with this cell type, make them
prohibitive as therapeutic agents. On the other end are the
adult stem cells, which still maintain a certain variability in
the scale of maturity, according to their source. Therefore,
bone marrow-derived stem cells present lower proliferative
capacity and less telomerase activity than stem cells derived
from adipose, dental pulp, and endometrial tissue. These,Journal of Biomedicine and Biotechnology 3
in turn, present more immature characteristics, expressing
embryonic markers and diﬀerentiating in vitro into cell types
from all three germ cell layers [1, 30].
3. Characterizationof
Endometrial-DerivedCells
The presence of stem cells in the endometrium was ﬁrst
d e s c r i b e do v e r3 0y e a r sa g o[ 31]. The monthly shedding of
the superﬁcial layers suggested that cells with high prolifer-
ating capacities were present in the tissue. The endometrium
is composed of epithelial cells, identiﬁed in the superﬁcial
layers of the tissue, and extending toward the interface with
themyometrium,throughthetubularglands.Theremaining
endometrium consists of stromal cells, smooth muscle cells,
endothelial cells, and leukocytes [32]. Functionally, the
endometrium can be divided in an upper layer, named func-
tionalis, which contains mostly glands loosely held together
by stromal tissue, and in a lower layer, basalis, consisting of
densestromaandbranchingglands.Thefunctionalisiselim-
inated monthly, as menstruation, and the basalis persists and
gives rise to the new endometrium, under hormonal inﬂu-
ence. Against the initial belief that the stem cells were exclu-
sively part of the basalis layer of the endometrium, and were
not eliminated with menstruation, Meng et al. [33]d e t e c t e d
stem cells in the menstrual blood. Several other studies fol-
lowed,conﬁrmingthediscovery[4,34,35]andconsolidating
menstrual blood as a possible source of stem cells.
Epithelial and stromal cells isolated from the endome-
t r i u mo rf r o mm e n s t r u a lb l o o da n dc u l t u r e din vitro show
clonogenicity and proliferative capacity, but the epithelial
cells soon lose part of their phenotypic markers and need
a feeder layer to survive [33, 36]. Patel et al. [4] published
a detailed study, in which stromal stem cells isolated from
menstrual blood (MenSCs) were expanded in vitro,a n d
showed clonogenic properties and multipotentiality. They
also demonstrated that MenSCs expressed markers of
pluripotency, such as Oct-4, SSEA-4, and c-kit, which are
frequently found in more immature cell types, including the
embryonic stem cells.
Recently, Allickson et al. [34] published a study about the
proliferative properties of human menstrual blood-derived
cells. Agreeing with previous studies, the cells presented
high proliferative rates and immature phenotype, expressing
embryonic cell markers, which remained unaltered after
20 culture passages. Interestingly, the cells demonstrated
resistance,sincetheywereabletobeprocessedupto96hours
after collection, high viability after processing, and longevity,
as some of the cultures were able to be subcultured 47 times
before senescence.
4. Experimentaland ClinicalApplications of
Endometrial-DerivedStemCells
Cui et al. published in 2007 the ﬁrst report of an in vivo
application of endometrial-derived cells. In this study, the
investigators evaluated the eﬀects of both endometrial cells
and menstrual blood cells in a murine model of Duchenne
muscular dystrophy. Fusion of the injected cells to myoblasts
was observed in vivo and in vitro, followed by the production
of human dystrophin by the treated muscle [35]. Shortly
after that, Hida et al. [10] described their experience in
diﬀerentiating menstrual blood-derived stromal cells in vitro
into spontaneously beating cardiomyocyte-like cells. When
menstrual blood cells were injected in the ischemic tissue of
myocardial infarct rat models, functional improvement was
noted, diﬀerently than what was observed when bone mar-
row stromal cells were used. Additionally, they compared the
phenotype and proliferative characteristics of endometrial
gland mesenchymal cells and menstrual blood mesenchymal
cells, concluding that they are very similar populations of
cells, the latter possibly deriving from the former. Finally,
the authors also described cell engraftment and transdiﬀer-
entiation into cardiac tissue, which seems to be a unique
characteristic of this transplantation site, since other studies
transplanting endometrial-derived cells into diﬀerent tissues
failed to detect expressive diﬀerentiation [11].
Regarding neurovascular disorders, Borlongan et al. [11]
reported the results of menstrual blood cell transplantation
in experimental stroke. Stromal-like menstrual blood stem
cells were isolated, expanded, and selected for CD117, a
marker associated with high proliferation, migration, and
survival [37]. In vitro studies showed that the expanded
cells maintained expression of embryonic-like stem cell
phenotypic markers, such as Oct4, SSEA-4, and Nanog,
even when cultured up to 9 passages, as an evidence of the
safety and reliability of these cells, and some were induced
to express neural markers (MAP2 and Nestin). Moreover,
when added to cultured rat neurons exposed to a hypoxic
insult, the menstrual blood cells provided neuroprotection,
and when applied to rat stroke models, less neurologic
deﬁcit was observed on functional tests, irrespective of the
injection site, that is, systemic or local administration into
the striatum. However, analysis of the tissue, after animal
sacriﬁce,revealedthat althoughhuman cellsweredetected in
theratbrain,somemigratingtoareasotherthantheinjected,
they did not show signs of diﬀerentiation, expressing their
original markers. The observation suggests that, at least
in the brain tissue, cell diﬀerentiation is not the main
mechanism of repair.
Wolﬀ et al. [13] reported the use of endometrial-derived
cells in a Parkinson’s disease mouse model. Endometrial-
derived stromal cells were diﬀerentiated in vitro into dopam-
inergic-like cells, which expressed nestin and tyrosine hy-
droxylase (TH), an enzyme that participates in dopamine
synthesis. Labeled human endometrium-derived cells and
prediﬀerentiated dopaminergic-like cells were transplanted
into the striatum of the animals. Endometrial-derived
stromal cells were able to migrate to the substantia nigra
and also showed signs of in vivo diﬀerentiation, acquiring
neuronal phenotype and expressing human TH. Taken
together, these observations demonstrate the therapeutic
potential of these cells to functionally restore the damaged
tissue. They also reinforce the idea that cells do not need
to be prediﬀerentiated before transplantation and that more
immature, less-diﬀerentiated cell types migrate easily to
the inﬂammatory sites. In contrast to the observations of4 Journal of Biomedicine and Biotechnology
Borlongan et al. [11], widespread cell diﬀerentiation was
suggested by this study.
The only clinical study yet published evaluated the safety
aspects of endometrial-derived stromal cells administration
[38]. Four patients with multiple sclerosis were treated with
intrathecal injections of 16 to 30 million cells, and one of the
patientsalsoreceivedanadditionalintravenousinjection.No
adverse events were registered and, in the short followup of
12 months, the authors reported functional stabilization.
Endometrium-derived cells present a strong angiogenic
potential that contributes to the experimental investigations
of vascular growth and remodeling and, perhaps, even for
designing clinical therapeutic studies, as these cells might be
applied to cardiovascular diseases. The angiogenic behavior
was already predicted by the observation of high levels
of VEGF and its receptors in the tissue and is probably
associated with the function of the cells in the endometrium,
that is, rapid proliferation and implantation of the embryo
[39]. In a pilot experimental study, Murphy et al. [12]
demonstrated that intramuscular injections of endometrial-
derived cells in hind limbs of rats were able to prevent the
formation of necrotic ulcers after ligation of the femoral
artery and its branches. The authors and others propose to
investigate the angiogenic properties of these cells in chronic
limb ischemia patients and, more recently, severe skin burns,
using the cells associated to intelligent artiﬁcial ﬁlms [40].
In summary, the available evidence regarding menstrual
blood-derived cells favors their future application in clinical
studies. In comparison to stem cells from other sources,
especially those from the bone marrow, menstrual blood-
derived stem cells have the advantage of presenting a more
immature phenotype, through the expression of embryonic-
like surface markers. Their immature behavior is conﬁrmed
by in vitro diﬀerentiation studies in which menstrual blood-
derived cells originate diverse tissue types from all three
germ layers [4, 33]. Moreover, they seem to have a higher
proliferative capacity, above 30 population doublings, when
compared to stromal cells from other sources, such as
the bone marrow and dental pulp, which are limited to
approximately 20 population doublings [1]. Additionally,
cultured menstrual blood cells maintain longer telomerase
activity than bone marrow-derived cells [4, 34], indicating
delayed senescence. These observations may reﬂect higher
regenerative and diﬀerentiation potentials in vivo,y e tt ob e
conﬁrmed by comparative studies between cells from diﬀer-
ent sources. Whether endometrial-derived stem cells provide
repair through cell diﬀerentiation or through paracrine
eﬀects, stimulating endogenous repairing pathways, is a
point still to be established. The available evidence suggests
that the type of tissue and possibly the nature of the injury
may determine the repairing mechanisms.
5. PersonalizedTherapy: PracticalAspects
Personalized medicine is a rapidly expanding ﬁeld oﬀering
patient-speciﬁc therapies to treat disease. Autologous cell
transplantation may be a form of personalized medicine that
could aﬀord many beneﬁts in the clinical setting, such as the
elimination of graft versus host disease. Transplantation of
autologous stem cells may circumvent the need for immuno-
suppressants, which can cause many deleterious side eﬀects
to the patient. Increased availability is another advantage
of autologous stem cell transplantation. Ethical controversy
surrounding the collection of a patient’s own stem cells is
greatlyreduced,thusincreasingtheaccessibilityofthesecells.
Unlike embryonic and fetal stem cells, harvesting autologous
stem cells from the patient does not harm another organism.
Embryonic stem cells carry an increased risk of tumor
formation, a characteristic not exhibited in autologous adult
stem cells. Increased safety and decreased ethical controversy
make autologous stem cells an appealing therapeutic option
for neurological disease. The debate currently surrounding
not only embryonic stem cell retrieval but also stem cell
usage in general has sparked issues with the usage. Obtaining
cells from a patient’s own body would circumvent the ethical
controversy as it is not harvesting viable cells from one
individual donor to another individual recipient, but it is
entirely for the same patient. Additionally, these cells would
not be taken in ways possibly deemed as “therapeutic cell
cloning,”suchasthecurrentdebatefollowingembryonicand
fetal stem cells.
Menstrual blood cells are a promising source of repair.
Theirimmaturebehaviorwarrantsmigration,immunomod-
ulation, secretion of growth factors, and, in some cases,
diﬀerentiation. These properties, coupled to the angiogenic
potential of the cells, make them attractive for restorative
approaches following ischemic stroke, as already demon-
strated by translational research [11]. Moreover, these cells
are optimal candidates for autologous therapy, following the
current trend to cryopreserve biological products intended
for future use. Although stromal cells have low immuno-
genicity due to the lack of MHC class II expression [41],
therefore enabling allogeneic application, autologous use
i ss t i l lp r e f e r r e d .S o m ea d v a n t a g e sa r eg u a r a n t e e dl a c k
of immunogenicity, reverting in longer cell survival and
no induction of local inﬂammatory reaction, safety, and
diminished risk of ethical conﬂicts.
The one-week time window that follows stroke seems the
best opportunity for cell therapy. While inﬂammation is at
its best degree, there is enough time to stabilize the patient,
complete physical examination and laboratory tests, discuss
the therapeutic options with the patient and family, and,
ﬁnally, apply the cells. Unfortunately, the time window is
still short for expansion of autologous cells in vitro, as the
procedure usually requires a few weeks to obtain minimum
number of cells. Menstrual blood cell banking, thus, seems
to be the best strategy and may become a strong competitor
to the already available umbilical cord blood banks.
Safety is one important concern regarding the use of
menstrual blood. Since the blood is collected through the
placement of a silicone cup inside the donor’s vagina, there-
fore exposed to microbial contamination, some precautions
are required, such as refrigeration of the collected specimens
and use of antibiotics [34]. Additionally, the cells should
be processed, expanded, and stored in a certiﬁed facility,
under strict rules of cleanliness and safety. Additional safety
measures include phenotypical veriﬁcation of the cells after
expansion, ensuring that they maintain the original markersJournal of Biomedicine and Biotechnology 5
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Figure 1: Isolation and transplantation of autologous menstrual blood-derived cells. Menstrual blood cells can be collected and stored prior
to injury or the development of a neurodegenerative disease. At the time of injury, the cells can then be thawed and expanded ex vivo. Once
the ideal number of cells has been reached, the autologous menstrual blood-derived cells can be transplanted into the patient.
andcytogeneticevaluations,excludingchromosomalaberra-
tions and microbiological tests.
A hypothetical scenario would be a woman, in postmen-
opausal age, recently aﬀected by an ischemic stroke. Due to
the limited timeframe between the beginning of symptoms
and ﬁnal diagnosis, she would be part of the majority of
patients that are excluded from tPA treatment. After further
examinations, evaluation of the extension of the infarct
and prognostic evaluations would be completed, estimating
the degree of future, long-term disability. Finally, given
the information that the patient has menstrual blood cells
cryopreserved and ready for use, the therapy would be
considered. After patient or familial consent, the cell bank-
ing facility would be contacted by the responsible physician,
settling date and time for the infusion. The cells would
be transported cryopreserved, being thawed at bedside
and immediately infused intravenously, under physician
supervision and cardiorespiratory monitoring. A second
peripheral venous line would be available for emergency
medication, if needed. After infusion, the patient would stay
in the hospital during at least 24 hours, for adverse reaction
monitoring, especially due to the possible toxic eﬀects of
dimethyl sulfoxide (DMSO) used in cell cryopreservation
and to remaining traces of antibiotics in the cell suspension
(Figure 1). After discharge, periodical evaluations would
evaluate the patient’s progress, establishing goals for the
complimentary treatments such as physical and speech
therapies, nutrition, and, ﬁnally, ability to resume work.
For a stroke-aﬀected patient, the slightest improvement
in neurological function can be decisive for self-suﬃciency
and, even, for ability to work, which are ultimately translated
into ﬁnancial independence. Therefore, investing in cell
banking as a safety measure against possible future events
may be a wise and even proﬁtable step. While cell banking
is already widely accessible for umbilical cord blood, only
recently has it also become available for menstrual blood
cells. Women in child-bearing age may donate multiple sam-
ples of menstrual blood, enabling storage of large amounts
of cells for future use. As a further possibility, the cells
couldbeexpandedanddiﬀerentiatedintospeciﬁctissuesand
be ready for eventual transplantation use [42]. An eﬃcient
banking system for menstrual blood cells would require an
organized and updated registration system, enabling prompt
identiﬁcation and rapid retrieval of the cryopreserved cells,
just in time for therapeutic application.
6. Conclusions
T h er e s c u eo ft h ep e n u m b r aa r e aa f t e rs t r o k ei sd e c i s i v ef o r
functional outcome and a great opportunity for cell therapy
[16]. Stem cells promote functional restoration especially
through modulation of the activated immune system and
secretionoftrophicfactors[25].Althoughcelldiﬀerentiation
is observed in the experimental setting, its importance to the
ﬁnal outcome of the treatment is still undeﬁned. Menstrual
cells combine characteristics that are convenient for clinical
application and, in parallel with cells derived from other dis-
posable tissues, may have a role in the future investigations.
Cryopreservation of autologous cells for future use may be a
prudent strategy to those patients at risk of being aﬀected by
stroke. Obviously, menstrual blood as a source of autologous
cells is limited to women as the target patient population.
Despitethepotentialchallengesstilltoberesolved,thesecells
represent important therapeutic tools that may improve the
disease outcome, decreasing the mortality and morbidity of
stroke patients.
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